Trial Profile

A phase I study assessing Nociceptin/orphaning for the treatment of chronic peripheral neuropathic pain

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 02 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nociceptin (Primary)
Indications Neuropathic pain
Focus First in man; Pharmacokinetics
Sponsors Grunenthal

Most Recent Events

29 Jun 2026 Status changed from recruiting to completed as per Grunenthal media release.
29 Jun 2026 Results presented in the Grunenthal media release.
22 Oct 2024 According to a Grunenthal media release, company announced that the first participants have been enrolled in a first-in-human Phase I clinical trial. The results of this trial are expected in Q3 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com